Sorority Recruits Report Turning to GLP-1 Drugs Before Rush, While New Research Questions the Hype Beyond Weight Loss

College sorority recruitment has always come with pressure to look a certain way. Now some students say that pressure is pushing them toward prescription weight-loss drugs meant for diabetes and obesity, not sorority row.

A feature published in The Cut, titled "The Secret 'Ozempidemic' on Sorority Row" and cited by Fox News, interviewed three female students under pseudonyms who said they used compounded semaglutide or tirzepatide to improve their odds during rush. One told the outlet, "For many young women who have just arrived on campus, thinness feels like the ticket into the best possible college experience." Another said, "I didn't realize that someone who was 19 and also not super-overweight could get on it. I was like, 'I gotta hop on.'"

A former sorority recruiter quoted in the piece put it more bluntly: "It's like, 'Well, there's no excuse for people to be fat because they could just get a GLP-1.'"

That's three anonymous accounts describing a campus subculture, not a data set proving how widespread the practice actually is. No source in this reporting quantifies how many sorority hopefuls specifically are using these drugs. The numbers that do exist are broader.

What the Data Actually Show

A 2024 analysis published in JAMA found that 162,439 young adults ages 18 to 25 received at least one dispensed GLP-1 prescription in 2023. Women made up 76.4% of those patients, though that figure includes prescriptions for both diabetes and weight management, not cosmetic use specifically.

The 2025 Monitoring the Future survey, which tracks students in grades 8, 10, and 12, found 2% reported using a prescription GLP-1 medication and another 2% said they'd used one without a prescription. That's a real number worth watching, but it's not evidence of a sorority-specific epidemic.

Jay Campbell, a longevity and peptide expert, told Fox News Digital the drugs were "built to solve a metabolic crisis" but have been "hijacked as a cosmetic shortcut" by young people with normal body weight. "For someone who's metabolically dysregulated, they are a genuine medical intervention," he said. "But to a 20-year-old sorority member with a normal BMI, they look like an aesthetic hack in a syringe."

If healthy 19- and 20-year-olds with no metabolic problem are taking a powerful appetite-suppressing drug to hit a beauty standard for a social club, that's a legitimate public health question. These drugs carry documented risks including pancreatitis, gallbladder problems, kidney issues, and worsening of diabetic eye disease, according to clinicians at Mind Therapy Clinic. None of those risks disappear just because the person taking the drug isn't diabetic or obese.

The Bigger Picture Isn't As Clean As the Hype

While the sorority story focuses on cosmetic use, separate research is complicating the broader cultural narrative that GLP-1 drugs automatically transform people's lives once the weight comes off.

According to Rolling Out, researchers examined more than a decade of nationally representative health survey data on adults with diabetes who used GLP-1 medications between 2012 and 2023, tracking mental health, employment, marital status, and self-rated health after one year and after two-plus years. The result: little evidence of a reliable pattern connecting the medication to improvements in those broader life categories.

That doesn't mean the drugs don't work. Their effectiveness for weight loss and metabolic health is well established. What the research questions is whether physical change reliably cascades into better jobs, relationships, or mental health, an assumption baked into a lot of the cultural hype around these drugs.

Other studies cut the other way. Research on nearly 100,000 people in Sweden with both diabetes and a diagnosed mental health condition found those using certain GLP-1 medications had meaningfully lower odds of their depression or anxiety worsening over five years, according to Rolling Out. Separate research found single women starting GLP-1 treatment saw higher odds of entering a relationship within about a year and a half, and unemployed women saw higher odds of finding work. Notably, people who were already married or employed didn't see the same shifts, suggesting any benefit shows up mainly where there's room for life circumstances to change.

Physicians who prescribe these drugs regularly told Rolling Out their clinical experience doesn't always match the newer, more cautious findings. Many patients who lose significant weight report broader improvements in energy and self-perception day to day, even if population-level survey data doesn't capture it cleanly.

On the Psychiatric Side

Mind Therapy Clinic, in an analysis dated September 28, 2026, noted psychiatrists are increasingly interested in GLP-1 drugs for reasons beyond weight, including reduced binge eating and food cravings. But the clinic also flagged a real risk: these medications could encourage or reinforce restrictive eating patterns in people who don't need them medically, a concern directly relevant to healthy-weight college students using them to shed a few pounds before rush.

The unresolved question here isn't whether GLP-1 drugs work. It's who's actually getting them, through what channel, and under what medical supervision. Compounded versions obtained through telehealth or off-brand pharmacies, the kind students described to The Cut, don't carry the same FDA oversight as brand-name Ozempic or Wegovy prescribed for an approved diagnosis. No agency has announced a specific investigation into off-label cosmetic use among college students, and no source here quantifies how common it actually is on any given campus. That gap, more than the drug itself, remains untracked.